Evidence map›Paper›PMID 26945581›Full record

ArticleJournal of neuro-oncology2016

Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study.

Shamik Chakraborty, Christopher G Filippi, Tamika Wong, Ashley Ray, Sherese Fralin, A John Tsiouris, Bidyut Praminick, Alexis Demopoulos, Heather J McCrea, Imithri Bodhinayake and 3 more

Erratum issuedAbstract readCase ReportsClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 56 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 3 pooled it
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 3 syntheses or guidelines pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Nanotherapeutics for Alleviating Anesthesia-Associated Complications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Shamik ChakrabortyLenox Hill Brain Tumor Center, Lenox Hill Hospital, Northwell Health, New York, NY, USA.ORCID 0000-0002-8627-6598
Christopher G FilippiDepartments of Neurosurgery, Neurology, Radiology, and Pathology, Hofstra Northwell School of Medicine, Manhasset, NY, USA.
Tamika WongLenox Hill Brain Tumor Center, Lenox Hill Hospital, Northwell Health, New York, NY, USA.
Ashley RayLenox Hill Brain Tumor Center, Lenox Hill Hospital, Northwell Health, New York, NY, USA.
Sherese FralinLenox Hill Brain Tumor Center, Lenox Hill Hospital, Northwell Health, New York, NY, USA.
A John TsiourisDepartments of Neurosurgery and Radiology, Weill Cornell Medical College of Cornell University, New York, NY, USA.
Bidyut PraminickDepartments of Neurosurgery, Neurology, Radiology, and Pathology, Hofstra Northwell School of Medicine, Manhasset, NY, USA.
Alexis DemopoulosLenox Hill Brain Tumor Center, Lenox Hill Hospital, Northwell Health, New York, NY, USA.
Heather J McCreaDepartments of Neurosurgery and Radiology, Weill Cornell Medical College of Cornell University, New York, NY, USA.
Imithri BodhinayakeLenox Hill Brain Tumor Center, Lenox Hill Hospital, Northwell Health, New York, NY, USA.
Rafael OrtizLenox Hill Brain Tumor Center, Lenox Hill Hospital, Northwell Health, New York, NY, USA.
David J LangerLenox Hill Brain Tumor Center, Lenox Hill Hospital, Northwell Health, New York, NY, USA.
John A BoockvarLenox Hill Brain Tumor Center, Lenox Hill Hospital, Northwell Health, New York, NY, USA. jboockvar@nshs.edu.
Northwell Health · USCornell University · USHofstra University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective To establish a maximum tolerated dose of superselective intraarterial cerebral infusion (SIACI) of Cetuximab after osmotic disruption of the blood-brain barrier (BBB) with mannitol, and examine safety of the procedure in patients with recurrent malignant glioma. Methods A total of 15 patients with recurrent malignant glioma were included in the current study. The starting dose of Cetuximab was 100 mg/m(2) and dose escalation was done to 250 mg/m(2). All patients were observed for 28 days post-infusion for any side effects. Results There was no dose-limiting toxicity from a single dose of SIACI of Cetuximab up to 250 mg/m(2) after osmotic BBB disruption with mannitol. A tolerable rash was seen in 2 patients, anaphylaxis in 1 patient, isolated seizure in 1 patient, and seizure and cerebral edema in 1 patient. Discussion SIACI of mannitol followed by Cetuximab (up to 250 mg/m(2)) for recurrent malignant glioma is safe and well tolerated. A Phase I/II trial is currently underway to determine the efficacy of SIACI of cetuximab in patients with high-grade glioma.

Indexed as

AdultAgedAntineoplastic Agents, ImmunologicalBlood-Brain BarrierBrain NeoplasmsCetuximabDiuretics, OsmoticDrug Therapy, CombinationFemaleGliomaHumansInfusions, Intra-ArterialMaleMannitolMaximum Tolerated DoseMiddle AgedAntineoplastic Agents, ImmunologicalCetuximabDiuretics, OsmoticMannitolBrain neoplasmCetuximabGliomaIntraarterial infusionMannitol

Identifiers

PMID26945581
OpenAlexW2289290132

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.